Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Medivir sharply increases liquidity after oversubscribed capital raise and finances three Phase II studies

Medivir reports liquidity of SEK 253.5m for Q2 2026 following an oversubscribed targeted share issue of about SEK 140m gross, which finances all three planned Phase II studies and, according to management, provides cash runway at least until 2030. The company recorded net revenue of SEK 1.2m and an operating loss of SEK 21.2m, a slight improvement year‑on‑year. Key pipeline milestones include publication of Fostrox data in Clinical Cancer Research, first patient treated in the FLEX‑HCC study in Korea, and expansion of MIV‑711 into Perthes disease. The stock reacted positively and rose sharply at times, with investors focusing on the improved financial position and clinical progress. » Altro su de.investing.com
Medivir cuts operating loss in Q1 2026 by 30% thanks to cost reductions

Medivir improved its operating result in the first quarter of 2026: the loss narrowed to -9.4 million SEK, a 30% improvement year-on-year, on net sales of 1.0 million SEK (+40%). Total operating costs fell 26% to 10.0 million SEK and cash position amounted to 149.1 million SEK. The company continues to focus on its Fostrox program (market potential ~2.5 billion USD for advanced HCC) and MIV-711 to address an unmet medical need in osteogenesis imperfecta. » Altro su de.investing.com
Medivir increases revenue and reduces EBITDA loss in Q1

Medivir reported revenue of SEK 1 million in the first quarter, a reduced EBITDA loss of SEK 8.80 million and an adjusted free cash flow of SEK -13 million. In February the company completed a directed share issue of SEK 45 million; cash and cash equivalents rose to SEK 149.1 million at the end of the quarter. Medivir plans to start a phase-2 proof-of-concept study for MIV-711 in osteogenesis imperfecta and a randomized second-line study of Fostrox in liver cancer; results from a veterinary study of MIV-701 are expected in Q4 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Medivir B ha già distribuito 0,26 € di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Medivir B ha registrato ricavi pari a 108,28K € e un utile netto di -1,81 Mln €

(EUR)	giu 2026	YoY
Ricavi	108,28K	19,56%
Utile lordo	-1,89 Mln	36,22%
Utile netto	-1,81 Mln	13,26%
EBITDA	-1,89 Mln	5,74%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	20,9 Mln €
Numero di azioni	114,24 Mln
Massimo/minimo a 52 settimane	0,66 € - 0,18 €
Dividendi	No
Beta	0,11
Rapporto P/E	-4,51
Rapporto PEG	-0,25
Rapporto P/B	2,09
Rapporto P/S	91,27

Profilo aziendale

Medivir AB (publ) erforscht, entwickelt und vertreibt in Schweden und international Arzneimittel vor allem zur Behandlung von Onkologie. Das Unternehmen vermarktet Xerclear für die Behandlung von Lippenherpes unter dem Namen Zoviduo. Außerdem entwickelt es Remetinostat zur Behandlung des kutanen MF-T-Zell-Lymphoms und des Basalzellkarzinoms. Darüber hinaus entwickelt das Unternehmen MIV-818 zur Behandlung von Leberkrebs, MIV-711 zur Behandlung von Osteoarthritis sowie Birinapant und IGM-8444 zur Behandlung von soliden Tumoren. Es unterhält eine Forschungskooperation mit der Drug Discovery and Development Platform bei SciLifeLab zur Entdeckung von Virostatika gegen SARS CoV-2 und eine Lizenzvereinbarung mit Tango Therapeutics für ein präklinisches Forschungsprogramm sowie mit Ubiquigent Limited für das präklinische Forschungsprogramm USP7. Medivir AB (publ) wurde 1987 gegründet und hat seinen Sitz in Huddinge, Schweden.